Which antipsychotic medication is FDA approved for schizophrenia and is considered to have a low risk for weight gain?

Aripiprazole (Abilify) is recognized for its favorable side effect profile compared to other antipsychotic medications, particularly in terms of weight gain. It is a partial agonist at the D2 dopamine receptor and has a unique mechanism of action, which contributes to its lower propensity for metabolic side effects, including weight gain.

Patients taking aripiprazole can often maintain a healthier weight compared to those on other antipsychotics known for inducing metabolic syndrome. This makes it a preferred choice for individuals who may be concerned about weight gain due to the medication, particularly in a population that may already struggle with obesity or its associated comorbidities.

Other antipsychotic options listed, while effective, tend to have higher profiles of weight-related side effects. For instance, iloperidone has been associated with higher incidence rates of weight gain, and both lurasidone and cariprazine have moderate weight gain risks as well. Therefore, aripiprazole stands out as the best option among the choices given for a medication that treats schizophrenia while minimizing the risk of weight gain.